WARNINGS AND PRECAUTIONS (cont’d)
Use in Patients With Renal Impairment:
Nonvalvular Atrial Fibrillation: Avoid the use of XARELTO®
in patients with creatinine clearance (CrCl) <15 mL/min, since
drug exposure is increased. Discontinue XARELTO® in patients
who develop acute renal failure while on XARELTO®.
• Treatment of Deep Vein Thrombosis (DVT), Pulmonary
Embolism (PE), and Reduction in the Risk of Recurrence of
DVT and of PE: Avoid the use of XARELTO® in patients with
CrCl <30 mL/min due to an expected increase in rivaroxaban
exposure and pharmacodynamic effects in this patient
population.
• Prophylaxis of Deep Vein Thrombosis Following Hip or
Knee Replacement Surgery: Avoid the use of XARELTO® in
patients with CrCl <30 mL/min due to an expected increase in
rivaroxaban exposure and pharmacodynamic effects in this
patient population. Observe closely and pro \ H]